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Comparative genomic evidence for the involvement of
schizophrenia risk genes in antipsychotic effects
Y Kim1,2,8, P Giusti-Rodriguez1,2,8, JJ Crowley1,2,3,4,8, J Bryois5, RJ Nonneman1,2, AK Ryan1,2, CR Quackenbush1,2, MD Iglesias-Ussel1,2, 
PH Lee6, W Sun2,7, FP-M de Villena2 and PF Sullivan1,2,3,5
Genome-wide association studies (GWAS) for schizophrenia have identified over 100 loci encoding 4500 genes. It is unclear
whether any of these genes, other than dopamine receptor D2, are immediately relevant to antipsychotic effects or represent novel
antipsychotic targets. We applied an in vivo molecular approach to this question by performing RNA sequencing of brain tissue
from mice chronically treated with the antipsychotic haloperidol or vehicle. We observed significant enrichments of haloperidol-
regulated genes in schizophrenia GWAS loci and in schizophrenia-associated biological pathways. Our findings provide empirical
support for overlap between genetic variation underlying the pathophysiology of schizophrenia and the molecular effects of a
prototypical antipsychotic.
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INTRODUCTION
A major goal of human genome-wide association studies (GWAS)
is to identify potential therapeutic targets for common, complex
diseases. While genomic regions that reach genome-wide
significance explain only a small fraction of disease risk, many
nonetheless encode proteins that make effective drug targets.1
For example, a common genetic variant in HMGCR has a small
(~5%) but significant (P= 1× 10− 30) influence on low-density
lipoprotein levels; however, its inhibition by statins effectively
treats hyperlipidemia.2 Another example comes from one of the
earliest GWAS, which identified a common variant in the
complement factor H gene for age-related macular
degeneration3–5 that led to targeting the complement cascade
for the treatment of age-related macular degeneration.6
Schizophrenia is a chronic, severe and disabling brain disorder
that has a median morbid lifetime risk of 0.72%.7,8 The most recent
schizophrenia GWAS identified 108 genome-wide significant loci
encoding over 500 genes.9 Because screening these putative
schizophrenia risk genes for those that are disease- and
therapeutically relevant is a substantial task, we adopted an
alternative, in vivo molecular approach. We examined the overlap
between schizophrenia risk genes and their orthologous mouse
genes whose striatal expression was significantly altered following
chronic haloperidol treatment. We improved upon prior studies of
the effects of chronic antipsychotic exposure on gene expression
in the rodent brain (Supplementary Tables 1 and 2) by using a
better detection technology (RNA sequencing, RNA-seq) and
larger sample sizes to enable the detection of more subtle effects
(total N= 38 mice), and by examining several tissues including
striatum, whole brain and liver for comparative controls
(Supplementary Table 3). We provide evidence that schizophrenia
risk genes and pathways are relevant to haloperidol effects.
MATERIALS AND METHODS
The goal of this study was to evaluate the effects of chronic administration
of the antipsychotic haloperidol versus vehicle in mice. We have shown
that we can reliably administer human-like steady-state concentrations of
haloperidol.10–12 All experimental procedures were randomized to mini-
mize batch artifacts13 (for example, assignment to haloperidol or vehicle,
cage, order of dissection, RNA extraction and assay batch). Experimenters
were blind to the treatment status.
We focused on the striatum as it is relatively dense with dopaminergic
neurons and is a key site of action of the dopamine receptor antagonist
haloperidol14 (confirmation of choice of tissue is described in the
Discussion). We also evaluated whole brain (to measure effects outside
the striatum) and liver (to identify brain-independent and hepatic
alterations consequent to chronic xenobiotic administration). For striatal
samples, we use RNA-seq to comprehensively identify differential gene
expression resulting from chronic haloperidol exposure. For whole brain
and liver, we used gene expression microarrays, which provide an
inexpensive transcriptome evaluation (albeit with lesser dynamic range),
and correlate well with RNA-seq (mean r= 0.87 across 88 mouse brain
samples assayed with both methods).15
Mice
All animal work was conducted in compliance with the national guidelines
(Institute of Laboratory Animal Resources, 1996) and was approved by the
UNC Institutional Animal Care and Use Committee. The study design is
summarized in Supplementary Table 3. For striatal RNA-seq we chronically
treated mice with haloperidol (N= 16) or vehicle (N= 12). All striatal
samples were assayed using RNA-seq. Independent mice (N=20) were
used to collect whole brain and liver (left lobe) from mice per treatment
group for expression microarray analysis. To minimize the effects of the
estrus cycle and other sources of heterogeneity, we evaluated male C57BL/
6J mice (shipped at 6 weeks of age, Jackson Laboratory, Bar Harbor, ME,
USA) for both RNA-seq and microarray experiments. Animals were
maintained in standard environmental conditions (14-h light/10-h dark
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schedule, temperature 20–24 °C, and 40–50% relative humidity). Mice were
housed four per cage (two haloperidol and two vehicle treated) in
standard 20 cm×30 cm ventilated polysulfone cages with laboratory
grade Bed-O-Cob bedding. Water and Purina Prolab RMH3000 were
available ad libitum.
Haloperidol exposure
Eight-week-old mice were implanted with slow-release haloperidol pellets
(3.0 mg kg− 1 per day; Innovative Research of America; Sarasota, FL, USA)16
or vehicle and were treated for 30 days for a chronic haloperidol
administration paradigm. Pellets were implanted subcutaneously, centrally
above the scapulae, under isoflurane anesthesia and the incision sealed
with VetBond (3M, St Paul, MN, USA). We have previously demonstrated
that this procedure reliably yields human-like steady-state concentrations
of haloperidol in blood plasma and brain tissue, and that this results in
vacuous chewing movements (an established model of extrapyramidal
symptoms17) in C57BL/6J mice.10,11,12
Tissue collection
After 30 days of exposure to haloperidol or vehicle (12 weeks of age), mice
were killed by cervical dislocation without anesthesia (to avoid effects on
gene expression). All mice were killed between 0800 and 1200 hours,
immediately after removal from the home cage. Tissues were dissected
within 5 min of death, snap-frozen in liquid nitrogen and pulverized using
a BioPulverizer unit (BioSpec Products, Bartlesville, OK, USA). Tissues
collected were striatum, whole brain or liver (left lobe). Striatum and whole
brain were collected from separate animals. The striatum dissection
consisted of capturing a 2-mm-thick coronal section (Bregma coordinates
+1.0 to − 1.0), followed by manual isolation of the striatal region per mouse
brain atlas (Figure 1a).18 Left and right striatum were pooled for each
animal.
RNA-seq
Total RNA was extracted from the striatum using the Total RNA Purification
96-Well Kit (Norgen Biotek, Thorold, ON, Canada). RNA concentration was
measured by fluorometry (Qubit 2.0 Fluorometer, Life Technologies,
Carlsbad, CA, USA) and RNA quality was verified using microfluidics
(Bioanalyzer, Agilent Technologies, Santa Clara, CA, USA). Barcoded
libraries were created using Illumina (San Diego, CA, USA) TruSeq Stranded
mRNA Library Preparation Kit v2 with polyA selection using 1 μg total RNA
as input. Equal amounts of all barcoded samples were pooled to account
for lane and machine effects. This pool was sequenced on eight lanes of
the Illumina HiSeq 2000 (100 bp single-end reads). See Supplementary
Table 4 for alignment summary of post-quality control RNA-seq samples.
We mapped lane-level reads to the mouse genome (mm9) using
using a GeneTitan instrument according to the manufacturer's instructions.
As in our prior reports,15,25 we used robust multiarray average method in
the Affymetrix gene expression console to estimate normalized expression
levels (default settings, median polish and sketch-quantile normalization).
We excluded probes containing any known single nucleotide polymorph-
isms in C57BL/6J,26 resulting in 24 464 probe sets for analysis. We searched
for outliers using principal component analysis and hierarchical clustering
(R function hclust), and identified only one outlier in a liver sample. We
evaluated potential confounding variables by examining the relationship
between PC1–PC10 from the expression data and each variable. We found
that all potential confounders had minimal impact on gene expression in
the whole brain and liver. For unmeasured confounders, we performed
surrogate variable analysis.27 Surrogate variables 1 and 2 explained the
majority of variation in the residual from a model including haloperidol
treatment. We used the following model to identify genes displaying
differential expression: y = β0+β1drug+β2sv1+β3sv2+ε, where ‘drug’ is an
indicator of haloperidol exposure and ‘sv1’ and ‘sv2’ are the first two
surrogate variables. False discovery rate correction was applied to
transcript-based P-values to account for multiple statistical comparisons
(R package q-value).24
Differentially expressed genes and GWAS results
We used INRICH28 and MAGMA29 to test for enrichment of GWAS signals in
transcripts showing differential gene expression in haloperidol versus
vehicle. INRICH evaluates whether a given gene set or pathway has an
enrichment of smaller GWAS association P-values than expected by chance
(accounting for gene size, single nucleotide polymorphism density, linkage
disequilibrium (LD) and pathway size). MAGMA combines the GWAS
P-values for each gene (10 kb upstream to 1.5 kb downstream) into a
gene-level P-value and accounts for correlations between single nucleotide
polymorphisms based on the LD (using 1000 Genomes Project European
reference panel Phase 3 (ref. 30)). MAGMA applies a linear regression
framework to test whether gene sets are significantly associated with a
trait with respect to the rest of the genome or to some subset of genes.
The latter was performed, by adding a covariate consisting of all genes
located at the GWAS loci. To determine whether the significant enrichment
of schizophrenia GWAS was specific to schizophrenia, we performed
enrichment testing with INRICH using GWAS results from other psychiatric
disorders (autism, bipolar disorder, major depressive disorder and
Alzheimer’s disease; URLs)31–33 and non-psychiatric traits (height, body
mass index and type 2 diabetes; URLs).34,35 Because high LD and high gene
density in the major histocompatibility complex (MHC) may influence
these analyses, we performed enrichment tests with inclusion and
exclusion of the MHC region.
Functional enrichment analysis
We used ConsensusPathDB (release MM9 (11.10.2013) version for mouse)36
to test differentially expressed genes (false discovery rate qo0.1) for
enrichment in Gene Ontology, the Kyoto Encyclopedia of Genes and
Genomes, Reactome, WikiPathways, MouseCyc37 and drug–gene interac-
tion databases. Functional clustering analysis was performed separately on
up- and downregulated genes using a hypergeometric test to examine
whether overlap between our list of genes and those present in each
reference category was higher than that expected by chance. The
background gene list included genes assessed in our expression
experiment.
Gene co-expression network analysis
To explore higher-order interactions in an unbiased manner, we used
WGCNA38 (URLs). After removing transcripts with low expression levels, we
applied blockwiseModule function (power = 6). For striatum RNA-seq data,
we included genes with a TReC sum 450 across all samples and then fit a
negative binomal general linearized model for each gene using batch and
RNA integrity number as covariates. We applied WGCNA to the residuals
after subtracting the fitted values from original raw data. For the whole-
brain microarray data, we used 15 185 probe sets that had a mean log2-
transformed and normalized expression level 46.5 across all samples.
RESULTS
We performed RNA-seq of the striatal brain tissue from adult male
C57BL/6J mice chronically treated (30 days) with implanted
Tophat19 (v2.0.6, default parameters). Using samtools,20 we removed reads 
with quality score o10 or potential PCR duplicates, and a median of 87%
of the reads mapped uniquely to the genome (range: 79–91%). The eight 
aligned BAM files for each sample (one per lane) were highly correlated 
and merged into one BAM file for each sample. Mapped reads were 
summarized into gene-level expression estimates of total read count 
(TReC). TReC is the number of reads that overlapped exonic regions of a 
gene (using the R package isoform21). Ensembl gene models were used 
(release 67, URLs). This yielded summarized read counts for 26 252 genes. 
We excluded genes with low expression levels (sum of TReC across all 
samples o50), resulting in 17 209 genes for analyses. TReC data were 
normalized using the weighted trimmed mean of M-values scale-
normalization method in EdgeR.22 We tested for differential gene 
expression in the striatum using the negative binomial generalized linear 
model approach in EdgeR,22 with gene-wise dispersion applied.22,23 The 
drug effect was evaluated using log-likelihood statistics comparing null 
and alternative models. False discovery rate correction was applied to 
gene-based P-values to account for multiple comparisons (R package
q-value).24
Gene expression arrays
Total RNA was extracted from ~ 25 mg of powdered tissue from the whole 
brain using automated instrumentation (Maxwell 16 Tissue LEV Total RNA 
Purification Kit, Promega, Madison, WI, USA). RNA concentration was 
measured and RNA quality verified as described above. Whole-brain RNA 
from 20 male C57BL/6J mice (10 haloperidol, 10 vehicle) was hybridized to 
Affymetrix Mouse Gene 2.0 ST 96-Array Plate arrays (Santa Clara, CA, USA)
Consistent with our hypothesis that the overlap is largely
specific to schizophrenia, only nominal associations were seen
with a co-heritable condition, bipolar disorder, and no significant
enrichment was observed for GWAS loci from human studies of
autism, major depressive disorder, Alzheimer’s disease, height,
body mass index or type 2 diabetes mellitus (Supplementary
Table 9). Most genes overlapping schizophrenia GWAS loci were
downregulated (Figure 1b, 27 of 39 genes), and 15 genes were
located in a human multigenic locus associated with schizo-
phrenia. Therefore, these results provide support for plausible
target genes within multigenic loci along with hypotheses of the
direction of association.
We found that haloperidol-regulated genes are also enriched
for historical schizophrenia candidate genes. Figure 1c shows
genes with the greatest fold-change after chronic haloperidol
exposure (full list in Supplementary Table 10). Three genes
(CHRNA7, HTR2A and SLC6A4) are among the top 25 most studied
schizophrenia candidate genes41 (P= 0.00018) and eight (CARTPT,
CHRNA7, GABRA6, GSTT2, HTR2A, NTS, PENK and SLC6A4) are
among the 864 orthologous schizophrenia candidate genes in the
Figure 1. Schizophrenia risk genes and historical candidate genes are differentially expressed following chronic haloperidol exposure. (a)
Overlap between schizophrenia GWAS loci from the Psychiatric Genomics Consortium9 and one-to-one orthologous mouse genes with
altered expression following haloperidol (qo0.1). A significant enrichment was seen with striatum RNA-seq data (P= 0.0004), but not with
whole-brain expression data (P= 0.45). (b) Manhattan plot of schizophrenia GWAS results9 showing 39 differentially regulated genes following
chronic haloperidol exposure (red: increased, blue: decreased expression, qo0.1). Underlined genes are located in a multigenic GWAS locus.
Genes of note are highlighted with a light green arrow. (c) Mouse genes with the most significant change in expression following chronic
haloperidol exposure (all genes with qo0.05), ranked by fold-change. This list is significantly enriched for historical schizophrenia candidate
genes (◆ from SzGene database;42 from top 25 most studied candidate genes41). GWAS, genome-wide association studies; RNA-seq, RNA
sequencing.
haloperidol (N = 16) or vehicle pellets (N = 12). Additional mice 
were examined for differential RNA expression in whole brain and 
liver (N = 20 mice, Supplementary Table 3). We first examined two 
positive control genes (Drd2 and Nts), and found that both genes 
showed a striatum-specific increase in expression after chronic 
haloperidol exposure, as expected from prior studies39,40 
(Supplementary Table 5). We found that the transcriptional effects 
of chronic haloperidol exposure were brain-specific (Supplemen-
tary Figure 1) and most pronounced in the striatum (Supplemen-
tary Table 6). Haloperidol-regulated genes were enriched for 
orthologous schizophrenia GWAS risk loci (Figure 1a, INRICH 
P = 0.0004, MAGMA P = 0.0003, 32 loci, 39 genes, Supplementary 
Tables 7 and 8). This enrichment remains when the MHC region is 
excluded (INRICH P = 0.0006, MAGMA P = 0.0001). These effects were 
not seen in the whole brain (INRICH P = 0.45) or liver (INRICH 
P = 0.95), suggesting that these effects are anatomically specific. 
Although haloperidol-regulated and schizophrenia-associated genes 
tend to be expressed in the striatum, enrichment for schizophrenia 
GWAS loci remained significant when restricting the analysis to 
genes expressed in the mouse striatum (INRICH P = 0.0009).
In summary, by integrating human genetic findings and mouse
in vivo expression data, we provide evidence that some
schizophrenia risk genes may be involved in chronic effects of
haloperidol. Our findings suggest targets for antipsychotic drug
development (for example, genes highlighted in Figure 1b and
pathways in Supplementary Figure 8a). Our results support the
ongoing development of α7-nicotinic acetylcholine receptor
agonists for cognitive enhancement in schizophrenia,53 and
suggest that α6 is also a potential target, but this will require
further experimental molecular data. We also show that the
mouse can be a suitable and efficient model organism in which to
use human GWAS results to learn more about drug mechanisms
and to support compound development.
URLs
Psychiatric Genomics Consortium, http://pgc.unc.edu; human and
mouse homology, ftp://ftp.informatics.jax.org/pub/reports/index.
html#homology; mouse exon annotations, http://www.bios.unc.
edu/~weisun/software/isofrom_files/Mus_musculus.NCBI37.67_data.
zip. WGCNA, http://labs.genetics.ucla.edu/horvath/Coexpression
Network; NIMH Psychoactive Drug Screening Program, http://
pdsp.med.unc.edu/downloadKi.html. GIANT body mass index and
height (http://www.broadinstitute.org/collaboration/giant), DIA-
GRAM consortium type 2 diabetes results (http://diagram-con
sortium.org/downloads.html), Autism Spectrum Disorder Working
Group of the PGC (http://www.med.unc.edu/pgc/files/resultfiles/
pgcasdeuro.gz) and a pathway regulating the effects of acetylcho-
line and nicotine on dopaminergic neurons (http://www.wikipath
ways.org/index.php/Pathway:WP1602) and MAGMA (https://ctg.
cncr.nl/software/MAGMA). These data have been deposited in the
Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo),
accession GSE67755.
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